AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19261236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 19261236 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (moderate dose)
Number of subjects: 68
Study 16428536 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 125 mg IV
Number of subjects: 204
Study 16428536 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg IV
Number of subjects: 204
Study 16428536 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 125 mg IV and Parecoxib 40 mg IV
Number of subjects: 204
Study 15571548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound cue
Number of subjects: 49
Study 15571548 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cue
Number of subjects: 49
Study 15571548 — intervention group
Group type: COMPARATOR
Intervention: Low-risk elderly and younger subjects
Number of subjects: 49
Study 11433626 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone interview method
Number of subjects: 0
Study 11433626 — intervention group
Group type: COMPARATOR
Intervention: Mail-out/mail-back method
Number of subjects: 0
Study 10101927 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum cortisol concentration
Number of subjects: 0
Study 10101927 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 17-ketosteroid level
Number of subjects: 0
Study 10101927 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 0
Study 8159194 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine at a dose of 50 mg nightly
Number of subjects: 60
Study 8159194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine at a dose of 0.1 mg twice daily
Number of subjects: 60
Study 8159194 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 60
Study 3355198 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthralin in 0.0125% clobetasol propionate
Number of subjects: 35
Study 3355198 — intervention group
Group type: COMPARATOR
Intervention: Anthralin in Lassar's paste
Number of subjects: 35
Study 29730727 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Habits, Healthy Girls-Brazil (H3G-Brazil) intervention emphasizing 10 key nutrition and physical activity messages over 6 months.
Number of subjects: 253
Study 29730727 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention prior to follow-up assessment).
Number of subjects: 253
Study 29584681 — intervention group
Group type: EXPERIMENTAL
Intervention: Community resilience coalitions
Number of subjects: 16
Study 29584681 — intervention group
Group type: COMPARATOR
Intervention: Preparedness coalitions
Number of subjects: 16
Study 29584681 — intervention group
Group type: EXPERIMENTAL
Intervention: Both coalition types
Number of subjects: 16
Study 26698158 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieve Mapping Catheter
Number of subjects: 102
Study 26698158 — intervention group
Group type: COMPARATOR
Intervention: Lasso-guided procedure
Number of subjects: 102
Study 26698158 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation cryoballoon
Number of subjects: 102
Study 24382095 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset alcohol and drug users (n=122; 67%)
Number of subjects: 182
Study 24382095 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset alcohol and drug users (n=60; 33%)
Number of subjects: 182
Study 21830022 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofacilitation of Developmental Reaction (NFDR) approach
Number of subjects: 30
Study 21830022 — intervention group
Group type: COMPARATOR
Intervention: Neurodevelopmental Therapy (NDT)
Number of subjects: 30
Study 20051840 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day)
Number of subjects: 25
Study 20051840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17015043 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation coupled with the use of an inhaled bronchodilator
Number of subjects: 5887
Study 17015043 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5887
Study 15364322 — intervention group
Group type: EXPERIMENTAL
Intervention: SigmaSTR
Number of subjects: 700
Study 15364322 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxSTR
Number of subjects: 700
Study 15364322 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxSTPost
Number of subjects: 700
Study 15364322 — intervention group
Group type: EXPERIMENTAL
Intervention: High Risk categorization
Number of subjects: 700
Study 10840264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (notified of GDS scores, offered educational sessions)
Number of subjects: 2346
Study 10840264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 2346
Study 10840264 — intervention group
Group type: COMPARATOR
Intervention: Control group (not notified of GDS scores, usual care)
Number of subjects: 2346
Study 10840264 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2346
Study 9207721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with encapsulated short ragweed extract
Number of subjects: 23
Study 9207721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8401640 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrified catheter (EC)
Number of subjects: 24
Study 8401640 — intervention group
Group type: COMPARATOR
Intervention: Nelaton catheter
Number of subjects: 24
Study 3532799 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone 5 mg capsules twice weekly (Group A)
Number of subjects: 97
Study 3532799 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone 2.5 mg capsules three times weekly (Group B)
Number of subjects: 97
Study 3532799 — intervention group
Group type: COMPARATOR
Intervention: Gestrinone 2.5 mg vaginal tablets three times weekly (Group C)
Number of subjects: 97
Study 3532799 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone treatment overall
Number of subjects: 97
Study 3355003 — intervention group
Group type: EXPERIMENTAL
Intervention: TA surfactant
Number of subjects: 0
Study 3355003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31758329 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous regional arterial infusion (CRAI) of nafamostat mesilate (NM)
Number of subjects: 39
Study 31758329 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration (IV) of nafamostat mesilate (NM)
Number of subjects: 39
Study 31294868 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejuvenation of leukoreduced RBC units using Rejuvesol (pyruvate, inosine, phosphate, and adenine), warmed at 37°C for 60 minutes, followed by manual washing with saline adenine glucose mannitol solution.
Number of subjects: 0
Study 31294868 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejuvenated RBCs
Number of subjects: 0
Study 31294868 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejuvenation process
Number of subjects: 0
Study 27939544 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% orchardgrass (ORD)
Number of subjects: 4
Study 27939544 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% orchardgrass + 50% Japanese millet (MIL)
Number of subjects: 4
Study 27939544 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% orchardgrass + 50% brown midrib sorghum × sudangrass (SSG)
Number of subjects: 4
Study 27939544 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% orchardgrass + 25% millet + 25% sorghum × sudangrass (MIX)
Number of subjects: 4
Study 26456487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVT) - 3 monthly injections followed by PRN treatment
Number of subjects: 44
Study 26456487 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution (HD)
Number of subjects: 44
Study 26456487 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (IVT+HD)
Number of subjects: 44
Study 26456487 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab (IVT)
Number of subjects: 44
Study 23467506 — intervention group
Group type: EXPERIMENTAL
Intervention: BRU-training (Balance Rehabilitation Unit)
Number of subjects: 60
Study 23467506 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual falls prevention care)
Number of subjects: 60
Study 20836754 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training program
Number of subjects: 36
Study 20836754 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 36
Study 18466801 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 3730
Study 18466801 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 3730
Study 18466801 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Valsartan and Captopril
Number of subjects: 3730
Study 18466801 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 3730
Study 16534882 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (interferon (IFN‐alpha‐2b) 10 million units daily for 4 weeks followed by every other day for 20 weeks + ribavirin (600 or 800 mg/d) + polaprezinc (150 mg/d) for 24 weeks)
Number of subjects: 102
Study 16534882 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (interferon (IFN‐alpha‐2b) 10 million units daily for 4 weeks followed by every other day for 20 weeks + ribavirin (600 or 800 mg/d) for 24 weeks)
Number of subjects: 102
Study 16534882 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 102
Study 16534882 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy
Number of subjects: 102
Study 14735184 — intervention group
Group type: EXPERIMENTAL
Intervention: Debulking surgery followed by i.p. chemotherapy (5-FU 550 mg m(‐2) day(‐1) i.p. and LV 60 mg m(‐2) day(‐1) i.v.)
Number of subjects: 18
Study 14735184 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with i.v. 5-FU+LV or i.v. methotrexate+5-FU+LV
Number of subjects: 18
Study 14735184 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who underwent macroscopically radical surgery
Number of subjects: 18
Study 11518914 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole treatment
Number of subjects: 89
Study 9434694 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-stat strategy
Number of subjects: 182
Study 9434694 — intervention group
Group type: COMPARATOR
Intervention: pH-stat strategy
Number of subjects: 182
Study 8518220 — intervention group
Group type: EXPERIMENTAL
Intervention: iproplatin
Number of subjects: 62
Study 8518220 — intervention group
Group type: COMPARATOR
Intervention: carboplatin
Number of subjects: 62
Study 3106101 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle-stimulating hormone (FSH)
Number of subjects: 20
Study 3106101 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (0.3 ml twice a day subcutaneously for 14 days) followed by FSH
Number of subjects: 20
Study 29718333 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 29
Study 29718333 — intervention group
Group type: COMPARATOR
Intervention: Sham electroconvulsive therapy
Number of subjects: 29
Study 28318865 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior PMDI
Number of subjects: 46
Study 28318865 — intervention group
Group type: COMPARATOR
Intervention: Posterior PMDI
Number of subjects: 46
Study 25646872 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Medical Care (TI-Med) training
Number of subjects: 30
Study 25646872 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (delay) condition
Number of subjects: 30
Study 23462342 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga classes and daily home practice
Number of subjects: 355
Study 23462342 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, facility-based aerobic exercise training
Number of subjects: 355
Study 23462342 — intervention group
Group type: COMPARATOR
Intervention: Usual activity
Number of subjects: 355
Study 23462342 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplement
Number of subjects: 355
Study 23462342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 20653371 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation with an explicit outline
Number of subjects: 27
Study 20653371 — intervention group
Group type: COMPARATOR
Intervention: Presentation without an explicit outline
Number of subjects: 27
Study 18271952 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTHUG intervention implemented in 2005
Number of subjects: 0
Study 18271952 — intervention group
Group type: COMPARATOR
Intervention: Historical control (2003)
Number of subjects: 0
Study 18271952 — intervention group
Group type: COMPARATOR
Intervention: Procedural interventions in 2004
Number of subjects: 0
Study 18271952 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pre-FASTHUG period (2003-2004)
Number of subjects: 0
Study 18271952 — intervention group
Group type: COMPARATOR
Intervention: Comparison of median pneumonia rate after FASTHUG
Number of subjects: 0
Study 16984065 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antisecretory therapy
Number of subjects: 722
Study 16984065 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for Helicobacter pylori
Number of subjects: 722
Study 16984065 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antisecretory therapy followed by Helicobacter pylori testing if symptoms improved
Number of subjects: 722
Study 16984065 — intervention group
Group type: COMPARATOR
Intervention: Combination strategy to empirical antisecretory treatment
Number of subjects: 722
Study 16984065 — intervention group
Group type: COMPARATOR
Intervention: Combination strategy to H. pylori test alone
Number of subjects: 722
Study 14594788 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood ascorbate concentrations
Number of subjects: 1214
Study 14594788 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol, beta-carotene, or retinol
Number of subjects: 1214
Study 14594788 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary antioxidants measured by food-frequency questionnaire
Number of subjects: 1214
Study 11187916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, multi-agent remission induction, early intensification with weekly, high-dose asparaginase, cranial radiation, frequent vincristine/corticosteroid pulses, doxorubicin for high-risk patients.
Number of subjects: 1255
Study 11187916 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate during induction (protocol 87-01).
Number of subjects: 1255
Study 11187916 — intervention group
Group type: COMPARATOR
Intervention: High-dose 6-mercaptopurine during intensification (protocol 91-01).
Number of subjects: 1255
Study 9361611 — intervention group
Group type: EXPERIMENTAL
Intervention: J colonic pouch-anal anastomosis
Number of subjects: 40
Study 9361611 — intervention group
Group type: COMPARATOR
Intervention: Straight coloanal anastomosis
Number of subjects: 40
Study 1286496 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.7 mg, 7 ml)
Number of subjects: 240
Study 1286496 — intervention group
Group type: COMPARATOR
Intervention: Placebo (9 ml)
Number of subjects: 240
Study 2951796 — intervention group
Group type: EXPERIMENTAL
Intervention: Duovent (fenoterol and ipratropium bromide)
Number of subjects: 20
Study 2951796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31335741 — intervention group
Group type: EXPERIMENTAL
Intervention: Hou Gu Mi Xi (HGMX)
Number of subjects: 360
Study 31335741 — intervention group
Group type: EXPERIMENTAL
Intervention: HGMX + rabeprazole
Number of subjects: 360
Study 31335741 — intervention group
Group type: COMPARATOR
Intervention: Placebo + rabeprazole
Number of subjects: 360
Study 31335741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 31335741 — intervention group
Group type: EXPERIMENTAL
Intervention: HGMX
Number of subjects: 360
Study 29727480 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional disclosure condition
Number of subjects: 96
Study 29727480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer experience facts condition
Number of subjects: 96
Study 29727480 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation condition
Number of subjects: 96
Study 26922022 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (400 µg)
Number of subjects: 47
Study 26922022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (80 µg)
Number of subjects: 47
Study 26922022 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (salbutamol and ipratropium)
Number of subjects: 47
Study 26922022 — intervention group
Group type: COMPARATOR
Intervention: Placebo (400 µg)
Number of subjects: 47
Study 24304596 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity (PA)
Number of subjects: 785
Study 24304596 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 785
Study 24304596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 785
Study 24304596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 785
Study 24304596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbances
Number of subjects: 785
Study 24304596 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in MVPA over time
Number of subjects: 785
Study 24304596 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FMI
Number of subjects: 785
Study 24304596 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight children
Number of subjects: 785
Study 22804697 — intervention group
Group type: EXPERIMENTAL
Intervention: Background music played while drinking wine
Number of subjects: 0
Study 22804697 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 0
Study 20550616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral pulmonary vein antrum isolation (PVAI) with double Lasso technique and left atrial (LA) linear ablation in patients with persistent AF
Number of subjects: 534
Study 17192912 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA testing
Number of subjects: 2483
Study 17192912 — intervention group
Group type: EXPERIMENTAL
Intervention: DRE and TRUS
Number of subjects: 2483
Study 17192912 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate volume
Number of subjects: 2483
Study 15277966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumping stroke pattern
Number of subjects: 24
Study 15277966 — intervention group
Group type: EXPERIMENTAL
Intervention: Semicircular stroke pattern
Number of subjects: 24
Study 15277966 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing variables and negative power deflections
Number of subjects: 24
Study 11241803 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (i.v. 0.2 mg/kg b.w.)
Number of subjects: 10
Study 11241803 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo, 20 mL)
Number of subjects: 10
Study 11241803 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylate (i.v. 500 mg)
Number of subjects: 10
Study 9647934 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy in hypogonadal men
Number of subjects: 62
Study 9647934 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone in eugonadal men (male contraceptive clinical trial)
Number of subjects: 62
Study 9647934 — intervention group
Group type: COMPARATOR
Intervention: No testosterone administration in eugonadal men
Number of subjects: 62
Study 8304358 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking more than 7.5 miles per week
Number of subjects: 239
Study 8304358 — intervention group
Group type: COMPARATOR
Intervention: Walking less than 1 mile per week
Number of subjects: 239
Study 8304358 — intervention group
Group type: EXPERIMENTAL
Intervention: Current level of walking activity
Number of subjects: 239
Study 2658669 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg ethanol
Number of subjects: 44
Study 2658669 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 44
Study 31895002 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin plus mirabegron
Number of subjects: 676
Study 31895002 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin plus placebo
Number of subjects: 676
Study 31068229 — intervention group
Group type: EXPERIMENTAL
Intervention: Old fashioned oats (OFO)
Number of subjects: 30
Study 31068229 — intervention group
Group type: EXPERIMENTAL
Intervention: Steel-cut oats (SCO)
Number of subjects: 30
Study 31068229 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant oats (IO)
Number of subjects: 30
Study 31068229 — intervention group
Group type: COMPARATOR
Intervention: Cream of Rice (CR)
Number of subjects: 30
Study 31068229 — intervention group
Group type: COMPARATOR
Intervention: Honey Nut Cheerios (HNC)
Number of subjects: 30
Study 28454829 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided complete revascularization
Number of subjects: 885
Study 28454829 — intervention group
Group type: COMPARATOR
Intervention: Culprit lesion treatment-only strategy
Number of subjects: 885
Study 26829596 — intervention group
Group type: EXPERIMENTAL
Intervention: POR*1/*1 genotype
Number of subjects: 229
Study 26829596 — intervention group
Group type: EXPERIMENTAL
Intervention: POR*1/*28 genotype
Number of subjects: 229
Study 26829596 — intervention group
Group type: EXPERIMENTAL
Intervention: POR*28/*28 genotype
Number of subjects: 229
Study 26829596 — intervention group
Group type: COMPARATOR
Intervention: CYP3A5 expressing KTR
Number of subjects: 229
Study 24267005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk (100 IU vitamin D, 500 mg calcium per 200 mL)
Number of subjects: 410
Study 24267005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified orange juice (100 IU vitamin D, 500 mg calcium per 200 mL)
Number of subjects: 410
Study 24267005 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement (200 IU vitamin D, 500 mg calcium)
Number of subjects: 410
Study 24267005 — intervention group
Group type: COMPARATOR
Intervention: Plain milk
Number of subjects: 410
Study 24267005 — intervention group
Group type: COMPARATOR
Intervention: Fortified milk
Number of subjects: 410
Study 24267005 — intervention group
Group type: COMPARATOR
Intervention: Fortified orange juice
Number of subjects: 410
Study 22587997 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Number of subjects: 677